Deferiprone


Concise Prescribing Info
Indications/Uses
Iron overload in patients w/ thalassaemia.
Dosage/Direction for Use
Adult : PO 25 mg/kg tid, adjust according to response. Max: 100 mg/kg/day.
Dosage Details
Oral
Iron overload in patients with thalassaemia
Adult: 25 mg/kg tid, may be adjusted according to response and therapeutic goals. Max: 100 mg/kg daily.
Administration
May be taken with or without food.
Contraindications
Neutropenia (including history of recurrent cases), history of agranulocytosis. Pregnancy and lactation.
Special Precautions
Immunocompromised patients. Hepatic and renal impairment.
Adverse Reactions
Reddish-brown urine discolouration, abdominal pain, arthralgia, neutropenia, nausea, vomiting, diarrhoea, dyspepsia, increased ALT concentrations, headache, appetite change, asthenia, musculoskeletal pain, peripheral oedema, dizziness, somnolence, pruritus, urticaria.
Potentially Fatal: Agranulocytosis.
Patient Counseling Information
This drug may cause reddish-brown discolouration of urine.
MonitoringParameters
Monitor serum ferritin every 2-3 mth, absolute neutrophil count (ANC) at baseline and wkly during treatment (if ANC <1500/mm3, monitor CBC, WBC and platelets daily until ANC recovery); ALT mthly, Zn level, signs/symptoms of infection.
Drug Interactions
Serum concentration may be increased by UGT1A6 inhibitors (e.g. phenylbutazone). May chelate polyvalent cations, allow at least 4-hr interval w/ antacids and mineral supplements containing Al, Fe or Zn. Risk of additive toxicity w/ drugs that may cause neutropenia or agranulocytosis.
Food Interaction
Absorption may be decreased when taken w/ foods containing Fe, Al and Zn.
Action
Description: Deferiprone is a chelating agent w/ high affinity to ferric ion (iron III). It binds w/ ferric ions to form neutral 3:1 (deferiprone:iron) complexes. It also has low affinity to other metals including copper, Al and Zn.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: Approx 1-2 hr.
Distribution: Volume of distribution: 1.6 L/kg. Plasma protein binding: <10%.
Metabolism: Metabolised by uridine diphosphate-glucuronosyltransferases (UGT)1A6 to the inactive metabolite, 3-O-glucuronide.
Excretion: Via urine (75-90%, as metabolite and Fe-deferiprone complex). Elimination half-life: Approx 2-3 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C. Protect from light. Any unused portions should be disposed of in accordance w/ local requirements.
ATC Classification
V03AC02 - deferiprone ; Belongs to the class of iron chelating agents. Used in iron overload.
Disclaimer: This information is independently developed by MIMS based on Deferiprone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in